CNS Pharmaceuticals Inc has a consensus price target of $20 based on the ratings of 1 analysts. The high is $20 issued by Maxim Group on September 12, 2025. The low is $20 issued by Maxim Group on September 12, 2025. The 2 most-recent analyst ratings were released by Maxim Group on September 12, 2025 and September 10, 2024, respectively. With an average price target of $10.25 between Maxim Group, there's an implied 42.36% upside for CNS Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for CNS Pharma (NASDAQ:CNSP) was reported by Maxim Group on September 12, 2025. The analyst firm set a price target for $20.00 expecting CNSP to rise to within 12 months (a possible 177.78% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for CNS Pharma (NASDAQ:CNSP) was provided by Maxim Group, and CNS Pharma upgraded their buy rating.
The last upgrade for CNS Pharmaceuticals Inc happened on September 12, 2025 when Maxim Group raised their price target to $20. Maxim Group previously had a hold for CNS Pharmaceuticals Inc.
The last downgrade for CNS Pharmaceuticals Inc happened on March 25, 2025 when Maxim Group changed their price target from N/A to N/A for CNS Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CNS Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CNS Pharma was filed on September 12, 2025 so you should expect the next rating to be made available sometime around September 12, 2026.
While ratings are subjective and will change, the latest CNS Pharma (CNSP) rating was a upgraded with a price target of $0.00 to $20.00. The current price CNS Pharma (CNSP) is trading at is $7.20, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.